First-generation somatostatin analogs (SSAs), such as octreotide (OCT), are the first line medical therapy for acromegaly. Pasireotide (PAS), a newly developed SSA, has shown promising results in the treatment of acromegaly.
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas
GATTO, FEDERICO;FERONE, DIEGO;
2017-01-01
Abstract
First-generation somatostatin analogs (SSAs), such as octreotide (OCT), are the first line medical therapy for acromegaly. Pasireotide (PAS), a newly developed SSA, has shown promising results in the treatment of acromegaly.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
In Vitro Head-to-Head Comparison Between Octreotide.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
863.21 kB
Formato
Adobe PDF
|
863.21 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
